Cornelius Cilliers, PhD

Director, Clinical Pharmacology
Mirati Therapeutics

I am Cornelius Cilliers, Ph.D., a Director of Clinical Pharmacology at Mirati Therapeutics in San Diego, California. I am the clinical pharmacology lead for adagrasib (KRAZATI, MRTX849), a KRAS G12C inhibitor that received FDA accelerated approval in December 2022, and MRTX0902, a SOS1 inhibitor in a Phase 1/2 FIH trial.

Poster(s):

• PII-195 - A PHASE 1 STUDY OF THE PHARMACOKINETICS OF ADAGRASIB IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT COMPARED TO SUBJECTS WITH NORMAL HEPATIC FUNCTION.
  Thursday, March 28, 2024

  5:00 PM – 6:30 PM MDT

• PII-196 - A PHASE 1 STUDY OF THE PHARMACOKINETICS OF ADAGRASIB IN SUBJECTS WITH MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT COMPARED TO SUBJECTS WITH NORMAL RENAL FUNCTION.
  Thursday, March 28, 2024

  5:00 PM – 6:30 PM MDT